The study was done by Yool Lee, Amita Sehgal, and colleagues at the University of Pennsylvania. The results provide mechanistic support for ‘chronotherapy,’ the delivery of cancer drugs timed to the endogenous circadian rhythm.
Circadian rhythms regulate many aspects of physiology from the organismic to the subcellular levels. Disruption of circadian rhythms, whether through jet travel, shift work, or sleep disturbances, is a known risk factor for several types of cancer.
In animal models, hormonally induced circadian disruption promotes tumour growth, but the underlying mechanism or mechanisms have not been clear.
To uncover potential mechanisms, the authors used the hormone dexamethasone to chronically advance daily rhythms in cultured cells. They found that treatment altered expression of multiple genes, especially those involved in regulating the cell cycle.
Circadian rhythm disruption increased cell proliferation, an effect that could be traced to increased expression of a cell-cycle control protein called cyclin D1. Cyclin D1, in turn, activated cyclin D-dependent kinase 4/6 (CDK4/6), a protein that switched the cell from growing larger to synthesizing new DNA, a step that ultimately leads to cell division.
The authors found that the tumour-fighting ability of one such drug, called PD-0332991, which inhibits CDK4/6 activity, varies with time-of-day such that treatment in the morning is more effective than treatment at night. Efficacy of PD-0332991 was reduced in both cells and mice when their circadian rhythms were disrupted.
She concluded saying, “Better understanding the molecular effects of jet lag, shift work, and other sources of chronic disruption may lead to strategies to minimise the increased cancer risk associated with these behaviours, and to better treatment strategies, including timing delivery of cancer therapy for maximum benefit.”
Source: Medical Xpress